Which weight for weight-based dosage regimens in obese patients?

被引：23

作者：

Erstad, BL ^{[1
]}

机构：

[1] Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2002年 / 59卷 / 21期

关键词：

D O I：

10.1093/ajhp/59.21.2105

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：2105 / 2110

页数：6

共 32 条

[11] Effects of obesity on pharmacokinetics - Implications for drug therapy [J].

Cheymol, G .

CLINICAL PHARMACOKINETICS, 2000, 39 (03) :215-231

[12] Adverse drug events in hospitalized patients - Excess length of stay, extra costs, and attributable mortality [J].

Classen, DC ;

Pestotnik, SL ;

Evans, RS ;

Lloyd, JF ;

Burke, JP .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :301-306

[13] OBESITY AND CARDIAC-FUNCTION [J].

DEDIVITIIS, O ;

FAZIO, S ;

PETITTO, M ;

MADDALENA, G ;

CONTALDO, F ;

MANCINI, M .

CIRCULATION, 1981, 64 (03) :477-482

[14] GENTAMICIN THERAPY [J].

DEVINE, BJ .

DRUG INTELLIGENCE & CLINICAL PHARMACY, 1974, 8 (11) :650-655

[15] ESTIMATING CREATININE CLEARANCE IN MORBIDLY OBESE PATIENTS [J].

DIONNE, RE ;

BAUER, LA ;

GIBSON, GA ;

GRIFFEN, WO ;

BLOUIN, RA .

AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1981, 38 (06) :841-844

[16] Remifentanil pharmacokinetics in obese versus lean patients [J].

Egan, TD ;

Huizinga, B ;

Gupta, SK ;

Jaarsma, RL ;

Sperry, RJ ;

Yee, JB ;

Muir, KT .

ANESTHESIOLOGY, 1998, 89 (03) :562-573

[17]

Metropolitan Life Insurance Company, 1959, STAT B METR INS CO, P1

[18] LEAN BODY-MASS AS A PREDICTOR OF DRUG-DOSAGE - IMPLICATIONS FOR DRUG-THERAPY [J].

MORGAN, DJ ;

BRAY, KM .

CLINICAL PHARMACOKINETICS, 1994, 26 (04) :292-307

[19]

MURPHY JE, 2001, CLIN PHARMACOKINETIC

[20] EFFECT OF ALTERED PLASMA-PROTEIN BINDING ON APPARENT VOLUME OF DISTRIBUTION [J].

OIE, S ;

TOZER, TN .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (09) :1203-1205

← 1 2 3 4 →